Development of ligand-targeted liposomes for cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 4, 2004, Pages 335-353

  Noble, Charles O ^a   Kirpotin, Dmitri B ^b   Hayes, Mark E ^b   Mamot, Christoph ^a   Hong, Keelung ^b   Park, John W ^a   Benz, Christopher C ^c   Marks, James D ^a   Drummond, Daryl C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Hermes Biosciences Inc   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Immunoliposomes; Ligand directed therapeutics; Ligand targeted liposomes; Receptor mediated endocytosis; Receptor targeted liposomes; Targeted drug delivery

Indexed keywords

ACRIDINE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; CETUXIMAB; CISPLATIN; CYTARABINE; CYTARABINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; EPITOPE; EVACET; GEMTUZUMAB OZOGAMICIN; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IBRITUMOMAB; IBRITUMOMAB TIUXETAN; IMMUNOLIPOSOME; LIGAND; LIPOSOME; LURTOTECAN; MITOXANTRONE; MYOLTARG; NAVELBINE; OLIGONUCLEOTIDE; PLASMID DNA; RETINOID DERIVATIVE; RITUXIMAB; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; INTERNALIZATION; MICELLIZATION; NONHUMAN; REVIEW; SOLID TUMOR; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; LIPOSOMES; NEOPLASMS;

EID: 4344646266     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.4.335     Document Type: Review

References (133)

1. DRUMMOND DC, MEYER OM, HONG K, KIRPOTIN DB, PAPAHADJOPOULOS D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. (1999) 51:691-743.
2. MUGGIA FM, HAINSWORTH JD, JEFFERS S et al.: Phase II study of liposomal doxorubicin in refactory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. (1997) 15:987-993.
3. RANSON MR, CHEESEMAN S, WHITE S, MARGISON J: Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit. Rev. Oncol. Hematol. (2001) 37:115-120.
4. CAMPOS SM, PENSON RT, MAYS AR et al.: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol. (2001) 81:206-212.
5. GORDON AN, FLEAGLE JT, GUTHRIE D et al.: Recurrent epithelia] ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. (2001) 19:3312-3322.
6. SAFRA T, GROSHEN S, JEFFERS S et al.: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer (2001) 91:90-100.
7. NORTHFELT DW, DEZUBE BJ, THOMMES JA et al.: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. (1997) 15:653-659.
8. MARTINO R, PEREA G, CABALLERO MD et al.: Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective Phase II study. Haematologica (2002) 87:822-827.
9. WOLLINA U, DRUMMER R, BROCKMEYER NH et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer (2003) 98:993-1001.
10. GILL PS, WERNZ J, SCADDEN DT et al.: Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. (1996) 14:2353-2364.
11. BATIST G, RAMAKRISHNAN G, RAO CS et al.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. (2001) 19:1444-1454.
12. SARRIS AH, HAGEMEISTER F, ROMAGUERA J et al.: Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing Phase II trial. Ann. Oncol. (2000) 11:69-72.
13. KEHRER DF, BOS AM, VERWEIJ J et al.: Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J. Clin. Oncol. (2002) 20:1222-1231.
14. ALLEN TM: Ligand-targeted therapeutics in anticancer therapy. Nat Rev. Cancer (2002) 2:750-763.
15. NORMANNO N, BIANCO C, DE LUCA A, MAIELLO MR, SALOMON DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer (2003) 10:1-21.
16. ROSS JS, GRAY K, GRAY GS, WORLAND PJ, ROLFE M: Anticancer antibodies. Am. J. Clin. Pathol. (2003) 119:472-485.
17. LOPES DE MENEZES DE, PILARSKI LM, ALLEN TM: In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. (1998) 58:3320-3330.
18. PARK JW, HONG K, KIRPOTIN DB et al.: Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. (2002) 8:1172-1181.
19. AHMAD I, LONGENECKER M, SAMUEL J, ALLEN TM: Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. (1993) 53:1484-1488.
20. ALLEN TM, HANSEN CB, LOPES DE, MENEZES DE: Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev. (1995) 16:267-284.
21. LYASS O, UZIELY B, BEN-YOSEF R et al.: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil®) in metastatic breast carcinoma. Cancer (2000) 89:1037-1047.
22. HOBBS SK, MONSKY WL, YUAN F et al.: Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA (1998) 95:4607-4612.
23. MATSUMURA Y, MAEDA H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. (1986) 46:6387-6392.
24. HUANG SK, LEE KD, HONG K, FRIEND DS, PAPAHADJOPOULOS D: Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. (1992) 52:5135-5143.
25. GABIZON A, CHEMLA M, TZEMACH D, HOROWITZ AT, GOREN D: Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J. Drug Target. (1996) 3:391-398.
26. MAYER LD, CULLIS PR, BALLY MB: In: Medical Applications of Liposomes. Papahadjopoulos La (Ed). Elsevier Science B.V., New York (1998).
27. SAPRA P, ALLEN TM: Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. (2003) 42:439-462.
28. GABIZON AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. (2001) 19:424-436.
29. MAMOT C, DRUMMOND DC, HONG K, KIRPOTIN DB, PARK JW: Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Updat. (2003) 6:271-279.
30. NIEHANS GA, SINGLETON TP, DYKOSKI D, KIANG DT: Stability of HER-2/neu expression over time and at multiple metastatic sites. J. Natl. Cancer Inst. (1993) 85:1230-1235.
31. KIRPOTIN D, PARK JW, HONG K et al.: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry (1997) 36:66-75.
32. HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA (1995) 92:1327-1331.
33. PRESS MF, CORDON-CARDO C, SLAMON DJ: Expression of the HERH2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 5:953-962.
34. ZHAO YY, SAWYER DR, BALIGA RR et al.: Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. (1998) 273:10261-10269.
35. DRUMMOND DC, HONG K, PARK JW, BENZ CC, KIRPOTIN DB: Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm. (2001) 60:285-332.
36. ROSS JF, CHAUDHURI PK, RATNAM M: Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer (1994) 73:2432-2443.
37. GOREN D, HOROWITZ AT, ZALIPSKY S et al.: Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer (1996) 74:1749-1756.
38. SAPRA P, ALLEN TM: Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. (2002) 62:7190-7194.
39. GOREN D, HOROWITZ AT, TZEMACH D et al.: Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. (2000) 6:1949-1957.
40. SUGANO M, EGILMEZ NK, YOKOTA SJ et al.: Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. (2000) 60:6942-6949.
41. BECERRIL B, POUL MA, MARKS JD: Toward selection of internalizing antibodies from phage libraries. Biochem. Biophys. Res. Commun. (1999) 255:386-393.
42. POUL MA, BECERRIL B, NIELSEN UB, MORISSON P. MARKS JD: Selection of tumor-specific internalizing human antibodies from phage libraries. J. Mol. Biol. (2000) 301:1149-1161.
43. LIEBERT M, WEDEMEYER. GA, STEIN JA et al.: Identification by monoclonal antibodies of an antigen shed by human bladder cancer cells. Cancer Res. (1989) 49:6720-6726.
44. KATARI RS, FERNSTEN PD, SCHLOM J: Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) horn serous effusions of patients with different types of carcinomas. Cancer Res. (1990) 50:4885-4890.
45. WALDMANN TA: Monoclonal antibodies in diagnosis and therapy. Science (1991) 252:1657-1662.
46. KIRPOTIN DB, PARK JW, HONG K et al.: Targeting of liposomes to solid tumors: the case of sterically stabilized anti-HER2 immunoliposomes. J. Liposome Res. (1997) 7:391-417.
47. NIELSEN UB, KIRPOTIN DB, PICKERING EM et al.: Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta. (2002) 1591:109-118.
48. LIU B, CONRAD F, COOPERBERG MR, KIRPOTIN DB, MARKS JD: Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. (2004) 64:704-710.
49. LEE RJ, HUANG L: Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. (1996) 271:8481-8487.
50. XU L, PIROLLO KF, CHANG EH: Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum. Gene Ther. (1997) 8:467-475.
51. ELIAZ RE, SZOKA FC Jr: Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. (2001) 61:2592-2601.
52. ZALIPSKYS, PUNTAMBEKAR. B, BOULIKAS P, ENGBERS CM, WOODLE MC: Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR. Bioconjug. Chem. (1995) 6:705-708.
53. MOREIRA JN, HANSEN CB, GASPAR R, ALLEN TM: A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta (2001) 1514:303-317.
54. WILLIS MC, COLLINS B, ZHANG T et al.: Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. (1998) 9:573-582.
55. SCHIFFELERS RM, KONING GA, TEN HAGEN TL et al.: Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release (2003) 91:115-122.
56. PASTORINO F, BRIGNOLE C, MARIMPIETRI D et al.: Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. (2003) 63:86-92.
57. ARAGNOL D, LESERMAN LD: Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl. Acad. Sci. USA (1986) 83:2699-2703.
58. HARDING JA, ENGBERS CM, NEWMAN MS, GOLDSTEIN NI, ZALIPSKY S: Immunogenicity and pharmacokinetic attributes of poly(ethyleneglycol)-grafted immunoliposomes. Biochim. Biophys. Acta (1997) 1327:181-192.
59. SHEETS MD, AMERSDORFER P, FINNERN R et al.: Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA (1998) 95:6157-6162.
60. BODER ET MIDELFORT KS, WITTRUP KD: Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. USA (2000) 97:10701-10705.
61. ALLEN TM: Liposomal drug formulations. Rationale for development and what we can expect in the future. Drugs (1998) 56:747-756.
62. LIM HJ, MASIN D, MCINTOSH NL, MADDEN TD, BALLY MB: Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS 180 solid tumors. J. Pharmacol. Exp. Ther. (2000) 292:337-345.
63. SHARMA A, STRAUBINGER RM: Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. (1994) 11:889-896.
64. GABIZON AA, BARENHOLZ Y, BIALER M: Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. (1993) 10:703-708.
65. WEBB MS, HARASYM TO, MASIN D, BALLY MB, MAYER LD: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer (1995) 72:896-904.
66. WEBB MS, SAXON D, WONG FM et al.: Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim. Biophys. Acta (1998) 1372:272-282.
67. MUI BL, CULLIS PR, PRITCHARD PH, MADDEN TD: Influence of plasma on the osmotic sensitivity of large unilamellar vesicles prepared by extrusion. J. Biol. Chem. (1994) 269:7364-7370.
68. LASIC DD, FREDERICK PM, STUART MC, BARENHOLZ Y, MCINTOSH TJ: Gelation of liposome interior: a novel method for drug encapsulation. FEBS Lett. (1992) 312:255-258.
69. CULLIS PR, HOPE MJ, BALLY MB et al.: Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta (1997) 1331:187-211.
70. ZALIPSKY S: Functionalized poly(ethlene glycol) for preparation of biologically relevant conjugates. Bioconjug. Chem. (1995) 6:150-165.
71. HARASYM TO, BALLY MB, TARDI P: Clearance properties of liposomes involving conjugated proteins for targeting. Adv. Drug Deliv. Rev. (1998) 32:99-118.
72. HANSEN CB, KAO GY, MOASE EH, ZALIPSKY S, ALLEN TM: Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta (1995) 1239:133-144.
73. ALLEN TM, BRANDEIS E, HANSEN CB, KAO GY, ZALIPSKY S: A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta (1995) 1237:99-108.
74. MARTIN FJ, HUBBELL WL, PAPAHADJOPOULOS D: Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. Biochemistry (1981) 20:4229-4238.
75. PARR MJ, ANSELL SM, CHOI LS, CULLIS PR: Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta (1994) 1195:21-30.
76. LEE RJ, LOW PS: Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta (1995) 1233:134-144.
77. LEE RJ, LOW PS: Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. (1994) 269:3198-3204.
78. GABIZON A, HOROWITZ AT, GOREN D et al.: Targeting folate receptor with folate linked to extremeties of poly(ethlene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. (1999) 10:289-298.
79. BLUME G, CEVC G, CROMMELIN MD et al.: Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta (1993) 1149:180-184.
80. MARUYAMA K, TAKIZAWA T, YUDA T et al.: Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta (1995) 1234:74-80.
81. ISHIDA T, IDEN DL, ALLEN TM: A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. (1999) 460:129-133.
82. IDEN DL, ALLEN TM: In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta (2001) 1513:207-216.
83. MAMOT C, DRUMMOND DC, GREISER U et al.: Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. (2003) 63:3154-3161.
84. SALOMON DS, BRANDT R, CLkRDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19:183-232.
85. MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy. Oncogene (2000) 19:6550-6565.
86. CIARDIELLO F, TORTORA G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. (2001) 7:2958-2970.
87. PARK JW, HONG K, KIRPOTIN DB et al.: Anti-HER2 immunoliposomes: enhanced efficay attributable to targeted delivery. Clin. Cancer Res. (2002) 8:1172-1181.
88. NEVE RM, NIELSEN UB, KIRPOTIN DB et al.: Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem. Biophys. Res. Commun. (2001) 280:274-279.
89. GUO Z, NOBLE CO, DRUMMOND DC et al.: HER2- and EGFR-targeted liposomal epirubicin. Proc. Am. Assoc. Cancer Res. (2003) 44:174.
90. MOREIRA JN, GASPAR R, ALLEN TM: Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim. Biophys. Acta (2001) 1515:167-176.
91. BRIGNOLE C, MARIMPIETRI D, GAMBINI C et al.: Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. (2003) 197:199-204.
92. PAGNAN G, MONTALDO PG, PASTORINO F et al.: GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer (1999) 81:268-274.
93. IINUMA H, MARUYAMA K, OKINAGA K et al.: Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer. (2002) 99:130-137.
94. RAFFAGHELLO L, PAGNAN G, PASTORINO F et al.: In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int. J. Cancer (2003) 104:559-567.
95. ALLEN TM, AHMAD I, LOPES DE MENEZES DE, MOASE EH: Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans. (1995) 23:1073-1079.
96. VINGERHOEDS MH, STEERENBERG PA, HENDRIKS JJ et al.: Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br. J. Cancer (1996) 74:1023-1029.
97. MOASE EH, QU W, ISHIDA T et al.: Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta (2001) 1510:43-55.
98. HYNES RO: A reevaluation of integrins as regulators of angiogenesis. Nat. Med. (2002) 8:918-921.
99. JANSSEN AP, SCHIFFELERS RM, TEN HAGEN TL et al.: Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int. J. Pharm. (2003) 254:55-58.
100. BENZINGER P, MARTINY-BARON G, REUSCH P et al.: Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro. Biochim. Biophys. Acta (2000) 1466:71-78.
101. BACKER MV, ALOISE R, PRZEKOP K, STOLETOV K, BACKER JM: Molecular vehicles for targeted drug delivery. Bioconjug. Chem. (2002) 13:462-467.
102. GREISER U, DRUMMOND D, MAMOT C et al.: Targeting immunoliposomes to endothelial receptors. Proc. Am. Assoc. Cancer Res. (2002) 43:414.
103. DRUMMOND DC, GUO Z, KIRPOTIN DB et al.: Immunoliposome delivery of novel anticancer compounds. Proc. Am. Assoc. Cancer Res. (2002) 43:418.
104. PASTORINO F, BRIGNOLE C, MARIMPIETRI D et al.: Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. (2003) 63:7400-7409.
105. HUANG L, VIROONCHATAPAN E: Introduction. Nonviral vectors for gene therapy (1999) Ch.1:3-22.
106. FELGNER PL, GADEK TR, HOLM M et al.: Lipofectin: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA (1987) 84:7413-7417.
107. STUART DD, ALLEN TM: A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability, Biochim. Biophys. Acta (2000) 1463:219-229.
108. HOFLAND HE, SHEPHARD L, SULLIVAN SM: Formation of stable cationic lipid/DNA complexes for gene transfer. Proc. Natl. Acad. Sci. USA (1996) 93:7305-7309.
109. MAURER N, WONG KF, STARK H et al.: Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J. (2001) 80:2310-2326.
110. ZHENG YR REIMER DL, ZHANG G, LEE PH, BALLY MB: Self-assembling DNA-lipid particles for gene transfer. Pharm. Res. (1997) 14:190-196.
111. HONG KL, ZHENG WW, BAKER A, PAPAHADJOPOULOS D: Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett. (1997) 400:233-237.
112. MONCK MA, MORI A, LEE D et al.: Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J. Drug Target (2000) 7:439-452.
113. STUART DD, KAO GY, ALLEN TM: A novel, long-circulating, and functional liposomal formulation of anti-sense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. (2000) 7-466-475.
114. TROS DE ILARDUYA C, ARANGOA MA, MORENO-ALIAGA MJ, DUZGUNES N: Enhanced gene delivery in vitro and in vivo by improved transferrin-lipoplexes. Biochim. Biophys. Acta. (2002) 1561:209-221.
115. REDDY JA, ABBURI C, HOFLAND H et al.: Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. (2002) 9:1542-1550.
116. LEAMON CP, COOPER SR, HARDEE GE: Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cells: Evaluation in vitro and in vivo. Bioconjug. Chem. (2003) 14:738-747.
117. KAO GY, CHANGE LJ, ALLEN TM: Use of targeted cationic liposomes in enhanced DNA delivery to cancer cells. Cancer Gene Ther. (1996) 4:250-256.
118. PASTORINO F, STUART D, PONZONI M, ALLEN TM: Targeted delivery of antisense oligonucleotides in cancer. J. Control. Release (2001) 74:69-75.
119. PASTORINO F, BRIGNOLE C, MARIMPIETRI D et al.: Targeted liposomal c-myc antisense oligonucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin. Cancer Res. (2003) 9:4595-4605.
120. TAN PH, MANUNTA M, ARDJOMAND N et al.: Antibody targeted gene transfer to endothelium. J. Gene Med. (2003) 5:311-323.
121. SHI N, PARDRIDGE W: Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA (2000) 97:7567-7572.
122. KIRPOTIN DB, PARK JW, HONG K et al.: In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (eds). Elsevier Science B. V., New York (1998).
123. MEYER O, KIRPOTIN D, HONG K et al.: Cationic liposomes coated with polyethylene glycol as carriers of oligonucleotides. J. Biol. Chem. (1998) 273:15621-15627.
124. BARRY MA, DOWER WJ, JOHNSTON SA: Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med. (1996) 2-299-305.
125. BOHL KULLBERG E, BERGSTRAND N, CARLSSON J et al.: Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug. Chem. (2002) 13:737-743.
126. ZHANG Y, JEONG LEE H, BOADO RJ, PARDRIDGE WM: Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med (2002) 4:183-194.
127. RUI Y, WANG S, LOW PS, THOMSON DH: Diplasmenylcholine-folate liposomes: an efficient vehicle for intracellular drug delivery. J. Am. Chem. Soc. (1998) 120:11213-11218.
128. HUWYLER J, WU D, PARDRIDGE WM: Brain drug delivery of small moleculaes using immunoliposomes. Proc. Natl. Acad. Sci. USA (1996) 93:14164-14169.
129. EAVARONE DA, YU X, BELLAMKONDA RV: Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J. Biomed. Mater. Res. (2000) 51:10-14.
130. MARTY C, ODERMATT B, SCHOTT H et al.: Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br. J. Cancer (2002) 87:106-112.
131. DAGAR S, KRISHNADAS A, RUBINSTEIN I, BLEND MJ, ONYUKSEL H: VIP grafted sterically sterilized liposomes for targeted imaging of breast cancer: in vivo studies. J. Control. Release (2003) 91:123-133.
132. SAPRA P, MOASE EH, MA J, ALLEN TM: Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin. Cancer Res. (2004) 10:1100-1111.
133. MATSUO H, WAKASUGI M, TAKANAGA H et al.: Possibility of the reversal of multidrug resistance and the aviodance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. J. Control. Release (2001) 77:77-86.